PATENT CLAIM ANALYSIS

Application Number: 15894546
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-07
Patent Classification: ["435", "006100"]

Abstract:
The invention relates to improved methods, devices, and kits for identifying and implementing an appropriate treatment regimen for subjects suffering from hypertension.

Claim (Index 77):
A method according to  claim 66  wherein a renin inhibitor is a urea derivative of a di- and tri-peptide, an amino acid or derivative, an amino acid chain linked by non-peptidic bonds, a peptidyl amino diol, a peptidyl beta-aminoacyl aminodiol carbamate, a diol sulfonamide, a sulfinyl compound, an N-morpholino derivative, an N-heterocyclic alcohol, a pyrrolimidazolone a pepstatin derivative, a fluoro- or chloro-derivative of a statone-containing peptide, enalkrein, RO 42-5892, A 65317, CP 80794, ES1005, ES 8891, SQ 34017, aliskiren ((2S,4S,5S,7S)\u2014N-(2-carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)phenyl]-oetanamid hemifumarate) SPP600, SPP630 and SPP635), or any combination thereof.

Metadata:
- Claim Count in Document: 80.0
- Percentile: 88.0
- Lexical Diversity: 1.13636
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15314641', '15037030', '10077870', '15813469', '13799682']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5382050821761176
- 35 USC 102 Novelty (BERT): 0.6182894826335716
- Combined Prediction Score: 0.546213522221863
- Mean Citation Score: 302.041664
- Max Citation Score: 652.6511
- Similarity Product: 465.71784635473495

Labels:
- Claim Label 101: 0
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test